Latest News for TCRT
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice A non-confidential investor presentation summarizing the preclinical dataset is now available FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos…
FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate.
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team SAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced the appointment of Melinda Lackey…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TCRT.
U.S. House Trading
No House trades found for TCRT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.